XFOR (X4 Pharmaceuticals) Interest Expense: $-8.81 Mil (TTM As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $4.05
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Interest Expense?

X4 Pharmaceuticals XFOR -0.98% 29 Interest Expense is $-8.81 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. X4 Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was $ -2.13 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.81 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. X4 Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $ -20.31 Mil. X4 Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $ -2.13 Mil. X4 Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

X4 Pharmaceuticals  (NAS:XFOR) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

X4 Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $-2.13 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-20.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $76.52 Mil.

X4 Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

X4 Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

X4 Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Interest Expense Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.64 -3.99 -5.78 -8.77 -8.88

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.20 -2.23 -2.26 -2.19 -2.13
XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-8.81 Mil mean?
X4 Pharmaceuticals (XFOR) has a Interest Expense of $-8.81 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Interest Expense too high?
X4 Pharmaceuticals' current Interest Expense is $-8.81 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Interest Expense compare to ZURA and LYEL?
X4 Pharmaceuticals' Interest Expense of $-8.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Interest Expense is $-8.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Interest Expense of $-8.81 Mil. The current Interest Expense is $-8.81 Mil. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Interest Expense is $-8.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.05
Price